TRAX peer analysis
First Tracks Biotherapeutics (TRAX) against its competitors: price, today's move, 1-year return and market value side by side.
TRAX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACRS Aclaris Therapeutics | $3.90 | 8.03% | 59.73% | $504.77M |
| ANAB AnaptysBio | $45.80 | 0.48% | 29.08% | $1.39B |
| ATTO Attovia Therapeutics | $15.27 | 1.80% | – | $694.81M |
| CLYM Climb Bio | $10.34 | 16.57% | 433.85% | – |
| ELDN Eledon Pharmaceuticals | $2.60 | 5.89% | -34.49% | – |
| IMUX Immunic | $7.64 | 4.37% | 7.35% | $105.88M |
| IMVT Immunovant | $29.10 | 2.50% | 29.24% | $6.30B |
| MLTX MoonLake | $11.60 | 7.41% | 9.07% | – |
| ODTX Odyssey Therapeutics | $19.23 | 1.85% | – | – |
| SABS SAB Biotherapeutics | $3.19 | 8.50% | -4.87% | – |
| TRAX First Tracks Biotherapeutics | $49.00 | 7.86% | – | – |
- TRAX's peers: ACRS (Aclaris Therapeutics), ANAB (AnaptysBio), ATTO (Attovia Therapeutics), CLYM (Climb Bio), ELDN (Eledon Pharmaceuticals), IMUX (Immunic), IMVT (Immunovant), MLTX (MoonLake).
Updated 2026-11-07 11:56 UTC